Ascentage Pharma Group International

Equities

6855

KYG0519B1023

Biotechnology & Medical Research

Delayed Hong Kong S.E. Other stock markets 10:03:26 2024-04-23 pm EDT			5-day change	1st Jan Change
16.88 ^HKD	+0.48%		+0.12%	-38.17%

Apr. 09	Ascentage Pharma Chairman Boosts Stake in Firm	MT
Apr. 04	Ascentage Pharma Group Directors Acquire Company Shares	MT

Ascentage Pharma Group International Announces Change of Principal Place of Business in Hong Kong

August 01, 2022 at 10:25 am EDT

The board of directors of Ascentage Pharma Group International announced that with effect from August 1, 2022, the principal place of business in Hong Kong of the Company will be changed to: Unit B, 17/F., United Centre, 95 Queensway, Admiralty, Hong Kong.

Latest news about Ascentage Pharma Group International

Ascentage Pharma Chairman Boosts Stake in Firm	Apr. 09	MT
Ascentage Pharma Group Directors Acquire Company Shares	Apr. 03	MT
Ascentage Pharma Widens Loss by Nearly 5% in 2023	Mar. 28	MT
Ascentage Pharma Group International Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Ascentage Pharma to Present Preclinical Results of Three Anti-Tumor Drugs at US Cancer Meet	Mar. 05	MT
Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting	Mar. 05	CI
Ascentage Pharma's Phase 3 Trial for Chronic Myeloid Leukemia Treatment Gets US FDA Nod; Shares Rise 3%	Feb. 14	MT
Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia	Feb. 13	CI
Ascentage Pharma Trustee Buys 100,000 Shares	Feb. 05	MT
Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia Management from the National Comprehensive Cancer Network	Jan. 16	CI
Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib	Dec. 14	CI
Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR	Dec. 10	CI
Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication	Nov. 24	CI
China Approves Ascentage Pharma's Chronic-Phase Chronic Myeloid Leukemia Treatment	Nov. 19	MT
China National Medical Products Administration Approves Olverembatinib for Treatment of Cml-Cp Patients	Nov. 17	CI
Ascentage Pharma Group Trustee Purchases 100,000 Shares Under Restricted Share Scheme	Nov. 16	MT
Ascentage Pharma Trustee Repurchases Shares	Nov. 15	MT
Ascentage Pharma Trustee Buys 50,000 Shares Under Restricted Share Scheme	Nov. 14	MT
Ascentage Pharma to Present Clinical Data on Hematological Drugs in US Meet	Nov. 02	MT
Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM	Nov. 02	CI
Ascentage Pharma Group International to Present Results from Multiple Clinical Studies of olverembatinib and APG-2575 at the 2023 American Society of Hematology(ASH) Annual Meeting, two of which have been Selected for Oral Reports	Nov. 02	CI
Ascentage Pharma Presents Lung Cancer Therapy Study at European Oncology Conference	23-10-24	MT
Ascentage Pharma Releases Latest Data of Pelcitoclax (Apg-1252) Combined with Osimertinib Demonstrates Potential as A New Treatment Option for Tp53-And Egfr-Mutant Nsclc	23-10-23	CI
Ascentage Pharma Announces First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia	23-10-17	CI
Ascentage Pharma and AstraZeneca Investment Co., Ltd. Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Combination with BTK Inhibitor Acalabrutinib in Treatment-Naïve Patients with First-Line CLL/SLL	23-10-15	CI

Chart Ascentage Pharma Group International

Duration

Period

Chart Ascentage Pharma Group International

More charts

Company Profile

Ascentage Pharma Group International is an investment holding company principally engaged in developing novel small therapies for cancers, hepatitis B virus (HBV) and certain age-related diseases. The Company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The Company's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The Company conducts businesses within the domestic market and to overseas markets, including the United States.

Sector

Biotechnology & Medical Research

Calendar

2024-08-19 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ascentage Pharma Group International

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.53 CNY

Average target price

27.24 CNY

Spread / Average Target

+75.38%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ASCENTAGE PHARMA GROUP INTERNATIONAL	-38.17%	602M
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	103B
REGENERON PHARMACEUTICALS, INC.	+3.31%	96.73B
ARGENX SE	+1.66%	21.31B
BIONTECH SE	-16.16%	21.21B
GENMAB A/S	-6.82%	18.79B
WUXI APPTEC CO., LTD.	-41.41%	16.37B
BEIGENE, LTD.	-22.87%	13.68B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	13.44B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.98B

Bio Therapeutic Drugs